The Best Performing S&P 500 Stocks Over the Past 30 Years Might Surprise You
A performance analysis of the current constituents of the S&P 500 Index Over the Last 30 Years ending September 2024 ...
Biogen and its investors both want US appeals court to clarify class certification
In a rare – and possibly unique – turn of events, both pharmacy company Biogen and its shareholders have asked a federal ...
Buy Rating Justified by Biogen’s Strategic Positioning and Strong Financial Outlook
Mizuho Securities analyst Salim Syed has maintained their bullish stance on BIIB stock, giving a Buy rating on September 24. Salim Syed has ...
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
However, the drugmaker's prospects look so strong that not only should it soon join the $1 trillion club, but it could even ...
Japan Today10d
Revolution or mirage? Controversy surrounds new Alzheimer's drugs
Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
Indiatimes15d
Revolution or mirage? Controversy surrounds new Alzheimer's drugs
Lecanemab, sold under the name Leqembi, was developed by US pharma firms Biogen and Eisai. Donanemab, developed by pharma giant Eli Lilly, is sold as Kisunla.
Couriermail16d
Revolution or mirage? Controversy surrounds new Alzheimer's drugs
A doctor working for Eli Lilly, who spoke on condition of anonymity, blamed its rival Biogen for overstating the benefits of previous treatment Aduhelm. The drug was controversially approved in ...